Nathan Rice

Stock Analyst at Piper Sandler

(3.09)
# 1,192
Out of 5,147 analysts
61
Total ratings
52.63%
Success rate
11.35%
Average return

Stocks Rated by Nathan Rice

Bank First
Jan 26, 2026
Maintains: Neutral
Price Target: $142$150
Current: $134.67
Upside: +11.38%
First Mid Bancshares
Nov 3, 2025
Maintains: Overweight
Price Target: $49$48
Current: $41.01
Upside: +17.04%
Merchants Bancorp
Oct 30, 2025
Maintains: Overweight
Price Target: $41$42
Current: $42.28
Upside: -0.66%
Byline Bancorp
Oct 28, 2025
Maintains: Overweight
Price Target: $34$35
Current: $31.20
Upside: +12.18%
CVS Health
May 2, 2024
Maintains: Buy
Price Target: $85$74
Current: $79.90
Upside: -7.38%
Nicolet Bankshares
Jan 10, 2024
Assumes: Neutral
Price Target: $84
Current: $152.76
Upside: -45.01%
Align Technology
Dec 11, 2023
Downgrades: Sell
Price Target: $197
Current: $190.10
Upside: +3.63%
Elanco Animal Health
Apr 25, 2023
Maintains: Sell
Price Target: $11$9
Current: $26.40
Upside: -65.91%
IDEXX Laboratories
Jul 21, 2022
Upgrades: Buy
Price Target: $530$435
Current: $656.73
Upside: -33.76%
The Cigna Group
Dec 14, 2021
Initiates: Neutral
Price Target: $233
Current: $289.82
Upside: -19.61%
Initiates: Neutral
Price Target: $83
Current: $44.88
Upside: +84.94%
Initiates: Overweight
Price Target: $15
Current: $19.63
Upside: -23.59%